A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)

Asahina, Hajime; Oizumi, Satoshi; Takamura, Kei; Harada, Toshiyuki; Harada, Masao; Yokouchi, Hiroshi; Kanazawa, Kenya; Fujita, Yuka; Kojima, Tetsuya; Sugaya, Fumiko; Tanaka, Hisashi; Honda, Ryoichi; Kikuchi, Eiki; Ikari, Tomoo; Ogi, Takahiro; Shimizu, Kaoruko; Suzuki, Masaru; Konno, Satoshi; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, Masaharu

A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)

Asahina, Hajime; Oizumi, Satoshi; Takamura, Kei et al.

Lung cancer, 2019, 138, 65-71

Permalink : https://hdl.handle.net/2115/79852

このアイテムのアクセス数:853件（2026-08-15 16:35 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数
Lung Cancer_138_65	pdf	300 KB	1,028
2019.09.20_HOT1302_supplemental figures_ver6	ppt	4.73 MB	242
2019.09.20_HOT1302_supple table_ver6	doc	56.0 KB	218

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/79852
タイトル	A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
著者	Asahina, Hajime ; Oizumi, Satoshi ; Takamura, Kei ; Harada, Toshiyuki ; Harada, Masao ; Yokouchi, Hiroshi ; Kanazawa, Kenya ; Fujita, Yuka ; Kojima, Tetsuya ; Sugaya, Fumiko ; Tanaka, Hisashi ; Honda, Ryoichi ; Kikuchi, Eiki ; Ikari, Tomoo ; Ogi, Takahiro ; Shimizu, Kaoruko ; Suzuki, Masaru ; Konno, Satoshi ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi ; Nishimura, Masaharu
e-Rad_Researcher 90374298 著者名 Asahina, Hajime
e-Rad_Researcher 10421968 著者名 Oizumi, Satoshi
著者名 Takamura, Kei
著者名 Harada, Toshiyuki
著者名 Harada, Masao
e-Rad_Researcher 60399946 著者名 Yokouchi, Hiroshi
著者名 Kanazawa, Kenya
著者名 Fujita, Yuka
著者名 Kojima, Tetsuya
著者名 Sugaya, Fumiko
著者名 Tanaka, Hisashi
著者名 Honda, Ryoichi
e-Rad_Researcher 60463741 著者名 Kikuchi, Eiki
著者名 Ikari, Tomoo
著者名 Ogi, Takahiro
e-Rad_Researcher 40399853 著者名 Shimizu, Kaoruko
e-Rad_Researcher 10374290 著者名 Suzuki, Masaru
e-Rad_Researcher 20399835 著者名 Konno, Satoshi
e-Rad_Researcher 70222528 著者名 Dosaka-Akita, Hirotoshi
e-Rad_Researcher 90241322 著者名 Isobe, Hiroshi
e-Rad_Researcher 00208224 著者名 Nishimura, Masaharu
言語	英語
キーワード	Non-small cell lung cancer
	Interstitial lung disease
	Carboplatin
	Nab-paclitaxel
	Clinical trial
発行日	2019-12
出版者	Elsevier
収録物名	Lung cancer
巻(号)	138
ページ	65-71
抄録	Objectives: Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospectively investigated the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin in patients with both advanced NSCLC and ILD. Patients and methods: The enrolled patients had treatment-naive, advanced NSCLC with ILD. Patients received 100 mg/m(2) nab-paclitaxel weekly and carboplatin at an area under the concentration-time curve of 6 once every 3 weeks for 4-6 cycles. The primary endpoint was the overall response rate (ORR); secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). Results: Thirty-six patients were enrolled between April 2014 and September 2017. Sixteen patients (44.4%) had adenocarcinoma, 15 (41.7%) had squamous cell carcinoma (Sq), and 5 (13.9%) had non-small cell carcinoma. The median number of cycles administered were 4 (range: 1-6). The ORR was 55.6% (95% confidence interval [CI]: 39.6-70.5). The median PFS and OS were 5.3 months (95% CI: 3.9-8.2) and 15.4 months (95% CI: 9.4-18.7), respectively. A greater proportion of patients with Sq experienced improvements than did those with non-Sq: ORRs, 66.7% (95% CI: 41.7-84.8) vs. 47.6% (95% CI: 28.3-67.6) (P = 0.254); median PFS, 8.2 months (95% CI: 4.0-10.2) vs. 4.1 months (95% CI: 3.3-5.4) (HR, 0.60 [95% CI, 0.30-1.20]; P = 0.15); and median OS, 16.8 months (95% CI: 9.8 not reached) vs. 11.9 months (95% CI: 7.3-17.4) (HR, 0.56 [95% CI, 0.24-1.28]; P = 0.17). Two patients (5.6%) experienced grade >= 2 pneumonitis and 1 patient (2.8%) died. Conclusion: Weekly nab-paclitaxel combined with carboplatin showed favorable efficacy with acceptable toxicity in patients with both advanced NSCLC and ILD.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0169-5002
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.lungcan.2019.09.020